Please ensure Javascript is enabled for purposes of website accessibility

Medicine Gets a Little More Personal

By Brian Orelli, PhD - Updated Apr 5, 2017 at 7:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Baby steps, however tiny, are still progress.

Amgen (NASDAQ:AMGN) and ImClone have already lost patients because of recent findings that their colon-cancer drugs don't work as well in patients who have mutated copies of the K-ras gene. Now they're hoping the FDA doesn't add insult to injury by making the companies add further proof through additional clinical trials.

Genentech (NYSE:DNA), seller of Herceptin for breast cancer, knew that the Her2 gene was an important factor in the efficacy of its drug. It even partnered with DAKO to develop a test for the expression of Her2 during clinical trials. However, the discovery that the patient's type of K-ras gene affects his or her response to Amgen's Vectibix and Bristol-Myers Squibb's (NYSE:BMY) and ImClone's -- now Eli Lilly's (NYSE:LLY) -- Erbitux is relatively new. An FDA panel meets tomorrow to help decide whether the current data is good enough to change the label of the drugs, or whether the drugs need additional clinical trials to prove that they work better in patients with "normal" K-ras genes.

Changing the drugs' labels won't be a too damaging to the companies in the long run. They've probably already lost many patients, because doctors already know the initial results and have begun testing patients. With the label change, the companies will be able to tout the data from the normal K-ras patients, for whom the results suggest that the drugs work better than chemotherapy. While they will likely lose some colon-cancer patients, they should also pick up even more normal K-ras patients who might have used other drugs -- or so ImClone believes.

Actually, the big beneficiary of a label change will be the companies that test for mutations in K-ras: Bio-Reference Laboratories (NASDAQ:BRLI), Genzyme (NASDAQ:GENZ), Exact Sciences and LabCorp (NYSE:LH). They're already getting some business from early adopting doctors, but a label change will convince most doctors that testing is needed for all patients.

As society tries to lower the cost of health care, it may increasingly begin to eliminate the use of drugs in patients who won't benefit. Personalized medicine is still in its infancy, but it's an emerging industry that should be huge in the long run.

Rule Breakers investing always seeks emerging industries. Grab a free 30-day trial to our future-focused growth-stock newsletter service to see all of our latest discoveries. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Eli Lilly is an Income Investor recommendation. LabCorp is a Stock Advisor selection. The Fool has a one-size-fits-all disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$303.54 (0.34%) $1.03
Amgen Inc. Stock Quote
Amgen Inc.
$248.74 (0.59%) $1.45
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$75.02 (1.65%) $1.22
Bio-Reference Laboratories Inc. Stock Quote
Bio-Reference Laboratories Inc.
Laboratory Corporation of America Holdings Stock Quote
Laboratory Corporation of America Holdings
$253.31 (-0.98%) $-2.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.